Author: Editor

Antonio Llombart-Cussac, MD, Ph.D.  founding partner of Medica Scientia Innovation Research (MedSIR) and the Hospital Arnau de Vilanova speaks about the SABCS 2020 Abstract – Palbociclib in Combination with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR+/HER2- Metastatic Breast Cancer: Detailed Safety Analysis from a Multicenter, Randomized, Open-Label, Phase II Trial (PARSIFAL).Abstract – The PARSIFAL study was an international, randomized, open-label phase II trial in patients with endocrine-sensitive, estrogen receptor-positive (ER[+]) and human epidermal growth factor receptor-2-negative (HER2[-]) metastatic breast cancer (HER2[-]) in patients with endocrine-sensitive, estrogen receptor-positive (ER[+]) and human epidermal growth factor receptor-2-negative (HER2[-]) metastatic breast cancer as…

Antonio Llombart-Cussac, MD, Ph.D.  founding partner of Medica Scientia Innovation Research (MedSIR) and the Hospital Arnau de Vilanova explains the SABCS 2020 Abstract – A Phase II Proof-of-Concept Study of Palbociclib Rechallenge in Patients with HR+HER2- Metastatic Breast Cancer and Clinical Benefit to Prior Palbociclib-Based Treatment BIOPER.Abstract – BIOPER was a multicenter, open-label, non-controlled phase II trial with two co-primary objectives: I To evaluate the clinical benefit of palbociclib plus endocrine therapy in patients with metastatic breast cancer who have previously received hormone therapy in combination with palbociclib and who have achieved clinical benefit after progression of the disease; (ii)…

Eunice S. Wang, MD of Roswell Park Comprehensive Cancer Center discusses the ASH 2020 abstract – 27 Phase 3, Multicenter, Open-Label Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy.Context:In patients with FLT3-mutated (FLT3mut+) relapsed/refractory acute myeloid leukemia (AML), including internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, Gilteritinib is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor that has demonstrated efficacy with favorable tolerability. Tumor growth and induced apoptosis and differentiation of FLT3 ITD AML cell lines and patient blasts in…

Christina Peters, MD, Professor of Paediatrics of St. Anna Children’s Hospital, and the Children’s Cancer Research Institute speaks about Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.ABSTRACT -PURPOSITY:In pediatric patients with acute lymphoblastic leukemia (ALL), total body irradiation (TBI) prior to allogeneic hematopoietic stem cell transplantation (HSCT) is successful, but long-term side effects are significant. We investigated whether, in such patients, preparatory combination chemotherapy could replace TBI.METHODS AND PATIENTS:FORUM is a non-inferiority, randomized, controlled, open-label, worldwide, multicenter, phase III sample. Myeloablative conditioning with fractionated 12 Gy TBI and etoposide versus fludarabine, thiotepa,…

Co-hosts Charu Aggarwal and Jack West are joined by Dr. Don Dizon to discuss the role social media plays in oncology, clinical trial enrollment and branding.

Prof. Dan Aderka of the Sheba Medical Center discusses the Optimal Sequence of Targeted Agents for All RAS & BRAF Patient Sub-types; Latest Data Update and Clinical Experience.https://virtualgi2020.com/congress-program/

Aung Naing, MD, FACP MD Anderson speaks about Strategies for improving the management of immune-related adverse events.You can download the IO Tox Management below -IOS -https://apps.apple.com/us/app/io-tox-management/id1514006592Android -https://play.google.com/store/apps/details?id=com.projectronin.iotoxman&hl=en_US&gl=USYou can find the full Abstract through the link below -https://jitc.bmj.com/content/8/2/e001754.fullInstractDurable and drastic responses in many difficult-to-treat malignancies have been observed with the advent of immunotherapeutic agents, outlining a path to overcoming cancer. Immune checkpoint inhibitors (ICPi) are a class of immunotherapy agents that, by reinvigorating the suppressed immune system, attack tumor cells. However, unbridled T-cell activity disrupts immune homeostasis and, in a large proportion of patients, causes a unique spectrum of side effects…

Jorge Cortes, MD, Director at the Georgia Cancer Center discusses U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML.CAMBRIDGE, Mass. & OSAKA, Japan—(BUSINESS WIRE)—Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) announced today that the United States has announced The supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) has been approved by the Food and Drug Administration (FDA) in adult patients with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or aversion to at least two prior kinase inhibitors. The revised label provides an integrated, response-based ICLUSIG dosing regimen in…

Robert M. Rifkin, MD of the Rocky Mountain Cancer Center speaks about the ASH 2020 Abstract – 3247 DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)Introducing:A B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate is Belantamab mafodotin (belamaf; GSK2857916). In the pivotal Phase II DREAMM-2 trial, single-agent belamaf showed strong, long-lasting responses and a manageable safety profile in patients who were refractory and/or intolerant to ~3 treatment lines, including monoclonal anti-CD38 antibodies such as daratumumab (Lonial et al. Lancet Oncol 2020). Responses were preserved…

Robert M. Rifkin, MD of the Rocky Mountain Cancer Center speaks about the ASH 2020 Abstract – 551 The Phase 3 TOURMALINE-MM2 Trial: Oral Ixazomib, Lenalidomide, and Dexamethasone (IRd) Vs Placebo-Rd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM).ContextIn transplant-ineligible NDMM patients, continuous Rd-based regimens are among the standards of treatment. These patients are diverse, ranging from healthy 70-plus-year-olds to elderly and/or vulnerable patients with low-performance status, requiring individual patient environments to be tailored to care. The continuous or higher cumulative dose use of proteasome inhibitors (PIs) contributes to improved long-term outcomes; however, long-term administration of injectable PIs can…

Jeffrey Skolnik, MD Inovio Pharmaceuticals discusses the Empower the Immune System to Treat Glioblastoma: DNA as Medicine.Information:  * Explore DNA drugs that can produce robust, antigen-specific T cell reactionsEvaluating the DNA medicine of Inovio, INO-5401 has promising early GBM data suggesting early efficacy and immunogenicity.Discuss the DNA medication of Inovio, its technology, and other promising approaches to GBM therapy.Dr. Skolnik supervises all the cancer immunotherapy services for Inovio, as well as those for other infectious diseases. Formerly at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, Dr. Skolnik supervised all oncology, infectious diseases,…

R. Stephanie Huang, Ph.D. of the University of Minnesota and R.S. Huang Lab discusses Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action.Lab website – http://huang-lab.umn.edu/Outline: Recently, evidence has emerged that many combinations of clinical cancer drugs can derive their effectiveness from independent drug action (IDA), where only the single most effective drug in a drug combination benefits patients. Here we present IDACombo, an IDA-based tool that uses monotherapy data from high-throughput cancer cell line screens to predict the effectiveness of drug combinations. In vitro (Pearson’s correlation = 0.93 when comparing predicted efficacy to observed…

Tammy Lo, NP from Norwalk Hospital speaks about Pancreatic Cancer and Reacts to Alex Trebek’s Death from the Disease.Pancreatic CancerCancer in the organ that lies behind the lower part of the stomach starts (pancreas).Enzymes that aid digestion and hormones that help control sugar metabolism are secreted by the pancreas. Sometimes, this form of cancer is discovered late, spreads easily, and has a poor prognosis.In the early stages, there are no signs. Symptoms are associated with later stages, but these may be non-specific, such as lack of appetite and loss of weight.Treatment may include removing the pancreas, radiation, and chemotherapy surgically.You…

Ron Peck, MD, Chief Medical Officer of Arvinas speaks about Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110.NEW HAVEN, Conn., 14 December 2020-Clinical-stage Arvinas, Inc. (Nasdaq: ARVN),The biopharmaceutical company that uses its PROTAC® Discovery Engine to build a new class of drugs focused on targeted protein degradation today revealed clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110. Interim Phase 1 results for ARV-471 indicate the potential for best-in-class protection and tolerability, degradation of the estrogen receptor (ER) higher than previously recorded for the current standard of care agent…

Prof. Matthias Preusser from the Medical University of Vienna discusses EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.InstractThe European Association of Neuro-Oncology (EANO) acknowledged the need to include revised recommendations for the diagnosis and treatment of adult patients with diffuse gliomas in response to significant developments in diagnostic algorithms and the publication of mature findings from numerous broad clinical trials. A task force of EANO offers guidance for the diagnosis, treatment, and follow-up of adult patients with diffuse gliomas through these evidence-based guidelines. The diagnostic portion is focused on the 2016 update of the WHO Central…

Javid Moslehi, MD and Justin M. Balko, Pharm.D., Ph.D. from Vanderbilt-Ingram Cancer Center discuss A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention.InstractCancer therapy has been transformed by immune control point inhibitors (ICI) targeting CTLA-4 or PD-1/PD-L1 but is associated with immune-related adverse effects (irAEs), including myocarditis. A robust preclinical mouse model of ICI-associated myocarditis is reported here, in which mono-allelic loss of Ctla4 in the sense of complete genetic absence of Pdcd1 leads to premature death in about half of the mice. Premature death results from T cell and macrophage myocardial invasion and…

Erika P. Hamilton, MD Director, Breast Cancer and Gynecologic Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology discussed the SABCS abstract – Tucatinib versus placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): outcomes by hormone receptor status.- New analyses from the pivotal HER2CLIMB analysis identify the hormone receptor status outcomes -BOTHELL, Wash.—(BUSINESS WIRE)—Seagen Inc. (Nasdaq: SGEN) today announced at the San Antonio Breast Cancer Symposium (SABCS) Virtual Symposium, held December 8-11, 2020, the presentation of new data from TUKYSA (tucatinib), its HER2-positive metastatic breast cancer treatment. Nine…

Charles L. Shapiro MD, FASCO, Professor of Medicine, Hematology, Medical Oncology and Director of Translational Breast Cancer Research Icahn School of Medicine at Mount Sinai speaks about the SABCS 2020 abstract – Postmenopausal Women With Early-stage Breast Cancer and Low Recurrence Score Could Skip Adjuvant Chemotherapy.SAN ANTONIO-After a median follow-up of 5.1 years, postmenopausal patients had no additional gain from chemotherapy among women with lymph node-positive early-stage breast cancer and a recurrence score of 25 or lower who received adjuvant endocrine therapy with or without chemotherapy, while premenopausal patients who received chemotherapy had increased invasive disease-free survival (IDFS) and chemotherapyWith…

Mazyar Shadman, M.D., M.P.H. from Fred Hutchinson Cancer Research Center discusses A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. For more information, click the link below -https://clinicaltrials.gov/ct2/show/NCT03277729?term=NCT03277729&draw=2&rank=1OUTLINE:This is a dose-escalation phase I/II analysis of CD20-specific therapy with CAR T cells.Patients undergo leukapheresis and, if necessary for disease control, can receive treatment afterward. Patients first undergo intravenous cyclophosphamide (IV). Fludarabine IV can also be given to patients. After 36-96 hours, patients undergo 20-30 minutes of CD20-specific…

Drs. West and Aggarwal host Dr. Nora Disis of Univ of Washington, Editor-in-Chief of JAMA Oncology as they discuss how academic publishing is evolving and challenges and opportunities for distributing medical research in a broader digital world.

Gerrit-Jan Liefers, MD of Leiden University Medical Center discusses the SABCS 2020 Abstract – The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in patients aged ≥70 years from the population-based observational FOCUS cohort.IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS-NOVEMBER 17, 2020-Agendia, Inc., a global pioneer in precision oncology for breast cancer, today announced that it would present new evidence from ongoing clinical trials examining the genomic studies of MammaPrint® and BluePrint® at the San Antonio Breast Cancer Symposium (SABCS 2020) on December 8-11, 2020.These statistics, based on current clinical studies demonstrating the effectiveness of MammaPrint and BluePrint testing…

Frankie Ann Holmes, MD, FACP from Texas Oncology-US Oncology Research speaks about Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS.Link to Poster -https://www.pumabiotechnology.com/docs/120920_PD3_03_Holmes_ExteNET_OS_SABCS_2020_poster_FINAL.pdfLOS ANGELES, Calif., December 11, 2020 / B3C newswire / — Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical firm, announced that at the current 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) the efficacy findings of neratinib in HER2-positive early-stage breast cancer (eBC) from the Phase III ExteNET trial were presented. A presentation entitled ‘Continued efficacy of neratinib in HER2-positive early-stage breast cancer patients: Final overall survival review from…

Jacob Scott, MD, DPhil of the Cleveland Clinic speaks about Combining Genomics and Mathematics Helps Personalize Radiation Therapy for Lung Cancer.Over the decades, clinical trials of lung cancer have determined an ideal “one size fits all” dosing scheme for patients treated with radiation therapy, TAMPA, Fla., and CLEVELAND, Ohio, but recent evidence now indicates that this is not as biologically reliable as once thought. For up to 75 percent of lung cancer patients, a new technique using tumor genomics to personalize radiation dosing suggests that the standard of care method could be suboptimal.A paper published in the Dec. 9 Journal…

Gelareh Zadeh, M.D., Ph.D., FRCS(C), FAANS, professor and dan chair of Neurosurgery at the University of Toronto, head of the Division of Neurosurgery at Toronto Western Hospital, and president of Society-of-Neuro-Oncology at the University of Toronto and Toronto Western Hospital discusses the SNO 2020 abstract – DNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for Neuro-oncology (SNO) Annual Meeting.HOUSTON, TX-November 9, 2020-DNAtrix, a pharmaceutical company developing virus-driven cancer immunotherapies, today announced that median overall survival of 12.5 months was demonstrated in Phase 2…

Maximilian Merz, MD from Roswell Park Comprehensive Cancer Center speaks about 722 Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma.Introducing:In multiple myeloma, care and immune-mediated procedures are associated with clonal evolution (MM). In this research, whole-exome sequencing (WES) and single-cell RNA sequencing (scRNA-seq) were performed on plasma cells (PC) from iliac crest (BM) bone marrow aspirates and corresponding osteolytic lesions (OL) to investigate spatial heterogeneity in newly diagnosed (NDMM) and relapsed/refractory MMM patients (RRMM). To examine the immunogenomic landscape surrounding malignant PCs, next-generation flow (NGF) and T-cell receptor sequencing (TCRseq) were performed.Methodology:In a prospective trial, in addition to the standard…

Pat Whitworth, MD of the Nashville Breast Center discusses the 5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival.HINTERGROUNDSMammaPrint (MP) distinguishes patients with breast cancer (BC) who can safely forego adjuvant chemotherapy. BC subtypes with distinct therapeutic response rates and survival results are characterized by MP combined with the BluePrint (BP) molecular subtyping signature. Compared to clinical IHC/FISH approaches, MP and BP reclassified 22 percent of tumors into a separate molecular subtype in the Neoadjuvant Breast Symphony Trial (NBRST). In addition, rates of pathologic complete response (pCR) to…

Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial 5 Key Conclusions: VS-6766 as a potential backbone of therapy for RAS pathway-driven cancers VS-6766 is a dual RAF/MEK with anti-tumor activity across multiple MAPK pathway alterations and multiple solid tumor indications VS-6766 + defactinib (FAKi) has shown 46% ORR (11/24) [64% ORR (7/11) in KRAS mt] with 23 months mPFS in LGSOC o Registration-directed clinical trial in progress (RAMP-201; NCT04625270) VS-6766 ± defactinib (FAKi) has shown 57% ORR (4/7) in KRAS G12V mt NSCLC o Registration-directed clinical trial in progress (RAMP-202; NCT04620330)…

Robert Zeiser, MD of the University Medical Center, Freiburg Im Breisgau discusses the ASH abstract – 77 Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study.REFERENCE:Systemic corticosteroids are used in routine first-line cGVHD therapy; however, about 50 percent of patients (pts) are refractory or reliant (SR/D) on steroids and need additional treatment. There is no description yet of the best second-line therapy choice.In a phase 3 trial, RUX, an oral JAK1/2 inhibitor, was superior to BAT in SR acute GVHD (aGVHD) (REACH2). The key review…

Andrew M. Evens, DO, MSc from Robert Wood Johnson University Hospital and Rutgers Cancer Institute of New Jersey discusses the ASH 2020 abstract – 476 Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era.Introducing:The treatment of older patients (pts) with PCNSL is complicated because of the prevalence of comorbidities, fragility, and difficulty of chemotherapy delivery (CT). For older PCNSL pts, the optimum induction CT and consolidation regimens are uncertain. In addition, few large-scale forecasting studies are available, including the study of geriatric evaluations (GA). In 17 academic centers, we…

Andrew M. Evens, DO, MSc from Robert Wood Johnson University Hospital and Rutgers Cancer Institute of New Jersey discusses the ASH 2020 abstract – 705 The Burkitt Lymphoma International Prognostic Index (BL-IPI).Context:BL is a rare, high-grade lymphoma of B cells that is mostly studied in limited sample size trials. Historical meanings of “low-risk BL” vary between studies, using lactate dehydrogenase (LDH) arbitrary cutoffs, and defining a small desirable subset, leaving >80-90% of patients (pts) in an undifferentiated category of “high-risk.” A validated prognostic index would help to compare the populations of the sample and better identify pts of good prognosis…

Frederick Locke, MD of the Moffitt Cancer Center & Research Institute speaks about the ASH 2020 abstract – 1187 Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel).Context:Axi-cel is an autologous T cell anti-CD19 chimeric antigen receptor (CAR) therapy approved for the treatment of patients (pts) with relapsed/refractory large B cell lymphoma (LBCL) with approximately 2 prior systemic therapies. ZUMA-1 is the Phase 1/2 multicenter, single-arm, registrational trial of axi-cel in refractory LBCL pts. Axi-cel demonstrated an objective response, full response (CR), and continuing response rates of 83…

Phillipe Moreau, MD from the University Hospital of Nantes discusses the ASH 2020 abstract – 2316 Isatuximab Plus Carfilzomib and Dexamethasone Vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IKEMA): Interim Analysis of a Phase 3, Randomized, Open-Label Study.Context:Relapsed/refractory multiple myeloma (RRMM) care has improved dramatically, but relapse is unavoidable, and additional successful therapies are required. Isatuximab (Isa), a monoclonal antibody targeting a particular CD38 epitope, is approved in conjunction with pomalidomide and dexamethasone (d) for the treatment of adult RRMM patients who have undergone at least two prior therapies, including lenalidomide and a proteasome inhibitor, in the United States,…

Steven W. Pipe, MD of the University of Michigan, Ann Arbor speaks about ASH 2020 abstract – Gene Therapy for Hemophilia B Found Safe and Effective in First Phase III Trial.(WASHINGTON, Dec. 8, 2020)-In the largest and most inclusive hemophilia B gene therapy trial to date, gene therapy etranacogene dezaparvovec dramatically improved the development of the blood-clotting protein factor IX among 52 patients. The study was also the first to include patients with such markers of the immune system and found that no elevated risks appeared to be conferred, a result that could greatly expand the number of patients eligible…

Cutaneous T cell lymphoma (CTCL), a heterogeneous group of non-Hodgkin lymphomas is a rare but aggressive cancer that manifests primarily in the skin and remains incurable with current standard therapies. Although there are therapeutic options available for early-stage CTCL, not all patients respond, resulting in refractory CTCL (rCTCL) with limited treatment options and a poor prognosis. The disease is usually slow-growing. The 2 most common types of this form of cancer are mycosis fungoides and Sézary syndrome. Each of the two forms of cutaneous T-cell lymphoma has unique characteristics that distinguish them from other types of non-Hodgkin’s lymphomas. A presentation…

Clint Valentine, MS from TwinStrand Biosciences discusses TwinStrand Biosciences Announces Peer-Reviewed Publication of Study Results Highlighting Ability of Duplex Sequencing Technology to Rapidly Detect the Mutagenic Activity of Chemicals.SEATTLE, Feb. 25, 2020 /PRNewswire/ — At the annual General Meeting of Advances in Genome Biology and Technology (AGBT) in Marco Island, Florida, TwinStrand BiosciencesTM, a next-generation DNA sequencing technology company, today announced the launch of TwinStrand Duplex SequencingTM Technology kits. At its launch, the company will offer its technology platform for two research applications: the identification of minimal residual diseases in patients with acute myeloid leukemia (AML MRD) and the multi-species…

Martin Dietrich, MD from Florida Cancer Specialists speaks about the FDA Approves FoundationOne®CDx as Companion Diagnostic for Vitrakvi® (larotrectinib), to Aid in Identifying NTRK Fusion-Positive Patients.WHIPPANY, N.J.—(BUSINESS WIRE)—According to Bayer, the U.S. Food and Drug Administration (FDA) approved FoundationOne®CDx for use as the first complementary diagnostic to help classify fusion-positive patients with neurotrophic receptor tyrosine kinase (NTRK) for whom Vitrakvi® (larotrectinib) treatment may be appropriate.1,2 FoundationOne CDx is an FDA-approved extensive genomic profiling (CGP) test for all solid tumors that includes multiple com com tumors.Vitrakvi is approved for the treatment of adult and pediatric patients with solid tumors who, without…

Philadelphia, PA (December 15, 2020) – Oncoceutics, Inc. announced today the outlicense of the rights to the company’s lead compound, ONC201, for Greater China to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (“CR Sanjiu”). In return for the license and future rights, CR Sanjiu will make a multi-part payment to Oncoceutics including upfront payments, milestone payments, and royalties. CR Sanjiu will also be responsible for the execution of clinical trials required to obtain Marketing Authorization in China and the commercialization of ONC201 in the Chinese market. ONC201, the company’s lead development candidate, is a novel small molecule with a unique mechanism…

Jyoti Nangalia, MBBChir of the Wellcome Sanger Institute, Hinxton, United Kingdom, University of Cambridge, Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom, and Cambridge Universities NHS Trust, Cambridge, United Kingdom speaks about the ASH 2020 abstract – LBA-1 Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms.Context:However the timing of driver mutations and the dynamics of the clonal expansion remain largely uncertain, but repeated mutations in cancer-associated genes drive tumour outgrowth. Philadelphia-negative myeloproliferative neoplasms (MPN) are distinct cancers that trace the earliest stages of tumorigenesis through the evolution of the disease. Most patients have…

Athena Kritharis, MD — she’s a Hematologist/Oncologist in the Hematologic Malignancies Program at Robert Wood Johnson University Hospital and Rutgers Cancer Institute of New Jersey speaks about the ASH 2020 abstract – LBA-4: Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs).Introducing:Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor with a new mechanism of action, unlike all licensed TKIs binding to the ATP site of…

Tycel J. Phillips, MD from Rogel Cancer Center, University of Michigan discusses the ASH 2020 abstract – 338 Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204).Context:Clinically heterogeneous, indolent, non-Hodgkin lymphoma (NHL) is a marginal zone lymphoma (MZL) with 3 subtypes known as extranodal, nodal, and splenic MZL. In a phase 1/2 study in patients with previously treated B-cell malignancies, Parsaclisib, an active, highly-selective, next-generation phosphatidylinositol 3 kinase (PI3K) δ inhibitor, has shown promising response rates. In patients with relapsed or refractory (R/R) MZL, CITADEL-204 (NCT03144674) is a multicenter,…

Rajat Bannerji, MD, Ph.D. Chief, Section of Hematologic Malignancies at Robert Wood Johnson University Hospital and Rutgers Cancer Institute of New Jersey, an expert in hematology/oncology, lymphoma and clinical trials Rutgers Cancer Institute of New Jersey speaks about the ASH 2020 Abstract – 400 Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy.REFERENCE: In a first-in-human study of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma, Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, completely human IgG4-based CD3 x CD20 bispecific antibody (bsAb) that…

Stephanie A. Cohen, MS, LCGC from Ascension St. Vincent discusses the ACCC/ASCO 2020 abstract – [Abstract #1526] BRCA Testing Concordance with National Guidelines for Patients with Breast Cancer in Community Cancer Programs.Context:Current National Comprehensive Cancer Network recommendations note that for women diagnosed with early-onset (about 45 years), later age (having met ethnic or family history criteria), or metastatic HER-2 negative breast cancer, checking for extremely penetrating breast/ovarian cancer genes is clinically suggested.A recent survey by the Association of Community Cancer Centers (ACCC) (N = 95) found that > 80 percent of respondents registered > 50% test rates for breast cancer…

We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer, Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon.Drs. West, Yu and Spigel discuss trial updates in lung cancer. For this video, the topic of discussion is current updates on combinations studies DREAM3R and RAMES, for potential treatments of mesothelioma.For more, please visit http://cancerGRACE.org/.…

We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer, Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon. Drs. West, Yu and Spigel discuss trial updates in small cell lung cancer. For this video, the topic of discussion is SCLC updates – new combinations of chemo-immunotherapy for extensive stage small cell lung…

Presented Live Online, December 5, 2020, GRACE Live Online OncTalk 2020 Connecting Lung Cancer Patients to the Experts Panel discussions featuring Immunotherapy and Combination Treatment Updates, SCLC, and Early and Locally Advanced NSCLC For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer, Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon. Drs. West, Yu and Spigel discuss trial updates in small cell lung cancer. For this video, the topic of discussion is SCLC and results from the Gronberg Study. The Gronberg study looked at lower…

Telemedicina y telesalud: cómo COVID 19 ha transformado la atención del cáncer En este video de discusión, el Dr. Narjust Duma habla con los Dres. Idalid “Ivy” Franco (Programa de Oncología Radioterápica de Harvard), Ana Velázquez Manana (Centro Integral de Cáncer Familiar Helen Diller de UCSF) y Luis Raez (Jefe de Hematología / Oncología y Director Médico – Memorial Cancer Institute). Para este video, los médicos analizan el COVID-19 y los cambios actuales en la telemedicina, y comparten recomendaciones para los pacientes con cáncer durante la pandemia. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.…

¿Qué sabemos sobre los efectos del COVID-19 en latinos con cáncer? Actualizaciones y recomendaciones. En este video de discusión, el Dr. Narjust Duma habla con los Dres. Idalid “Ivy” Franco (Programa de Oncología Radioterápica de Harvard), Ana Velázquez Manana (Centro Integral de Cáncer Familiar Helen Diller de UCSF) y Luis Raez (Jefe de Hematología / Oncología y Director Médico – Memorial Cancer Institute). Los médicos discuten la epidemiología y la cantidad actual de casos de COVID-19 en Latinx en los Estados Unidos y América Latina, y Covid y el cáncer en los latinos. Para obtener más información, visite http://cancerGRACE.org/. Para…